<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31775340</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>23</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Nov</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>McArdle Disease: New Insights into Its Underlying Molecular Mechanisms.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">5919</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms20235919</ELocationID>
        <Abstract>
          <AbstractText>McArdle disease, also known as glycogen storage disease type V (GSDV), is characterized by exercise intolerance, the second wind phenomenon, and high serum creatine kinase activity. Here, we recapitulate <i>PYGM</i> mutations in the population responsible for this disease. Traditionally, McArdle disease has been considered a metabolic myopathy caused by the lack of expression of the muscle isoform of the glycogen phosphorylase (PYGM). However, recent findings challenge this view, since it has been shown that PYGM is present in other tissues than the skeletal muscle. We review the latest studies about the molecular mechanism involved in glycogen phosphorylase activity regulation. Further, we summarize the expression and functional significance of PYGM in other tissues than skeletal muscle both in health and McArdle disease. Furthermore, we examine the different animal models that have served as the knowledge base for better understanding of McArdle disease. Finally, we give an overview of the latest state-of-the-art clinical trials currently being carried out and present an updated view of the current therapies.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Llavero</LastName>
            <ForeName>Francisco</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Sports Science, European University of Madrid, 28670 Madrid, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arrazola Sastre</LastName>
            <ForeName>Alazne</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Luque Montoro</LastName>
            <ForeName>Miriam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gálvez</LastName>
            <ForeName>Patricia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmascience Division, Technological Park of Health Sciences, Avda. de la Ciencia, s/n 18100 Armilla, Granada, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lacerda</LastName>
            <ForeName>Hadriano M</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>Three R Labs, Science Park of the UPV/EHU, 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parada</LastName>
            <ForeName>Luis A</ForeName>
            <Initials>LA</Initials>
            <AffiliationInfo>
              <Affiliation>Instituto de Patología Experimental, Universidad Nacional de Salta, Salta 4400, Argentina.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zugaza</LastName>
            <ForeName>José Luis</ForeName>
            <Initials>JL</Initials>
            <AffiliationInfo>
              <Affiliation>Achucarro Basque Center for Neuroscience, Science Park of the Universidad del País Vasco/Euskal Herriko Unibertsitatea (UPV/EHU), 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Genetics, Physical Anthropology, and Animal Physiology, Faculty of Science and Technology, UPV/EHU, 48940 Leioa, Spain.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.4.1.-</RegistryNumber>
          <NameOfSubstance UI="D024981">Glycogen Phosphorylase</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024981" MajorTopicYN="N">Glycogen Phosphorylase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006012" MajorTopicYN="N">Glycogen Storage Disease Type V</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">McArdle disease</Keyword>
        <Keyword MajorTopicYN="N">O-glycosylation</Keyword>
        <Keyword MajorTopicYN="N">glycogen phosphorylase</Keyword>
        <Keyword MajorTopicYN="N">glycogen storage disease type V</Keyword>
        <Keyword MajorTopicYN="N">hexosamine biosynthetic pathway</Keyword>
        <Keyword MajorTopicYN="N">small GTPases</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no conflicts of interest with the contents of this article. All authors qualify for authorship, approved the final version of the manuscript and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>11</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31775340</ArticleId>
        <ArticleId IdType="pmc">PMC6929006</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms20235919</ArticleId>
        <ArticleId IdType="pii">ijms20235919</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Lebo R.V., Anderson L.A., DiMauro S., Lynch E., Hwang P., Fletterick R. Rare McArdle disease locus polymorphic site on 11q13 contains CpG sequence. Hum. Genet. 1990;86:17–24. doi: 10.1007/BF00205166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00205166</ArticleId>
            <ArticleId IdType="pubmed">1701414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McArdle B. Myopathy due to a defect in muscle glycogen breakdown. Clin. Sci. 1951;10:13–35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24540673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellick R.S., Mahler R.F., Hughes B.P. McArdle’s syndrome: Phosphorylase-deficient myopathy. Lancet. 1962;1:1045–1048. doi: 10.1016/S0140-6736(62)92145-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(62)92145-1</ArticleId>
            <ArticleId IdType="pubmed">14472393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Castro M., Johnston J., Biesecker L. Determining the prevalence of McArdle disease from gene frequency by analysis of next-generation sequencing data. Genet. Med. 2015;17:1002–1006. doi: 10.1038/gim.2015.9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/gim.2015.9</ArticleId>
            <ArticleId IdType="pmc">PMC4561039</ArticleId>
            <ArticleId IdType="pubmed">25741863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santalla A., Nogales-Gadea G., Encinar A.B., Vieitez I., González-Quintana A., Serrano-Lorenzo P. Genotypic and phenotypic features of all Spanish patients with McArdle disease: A 2016 update. BMC Genom. 2017;18(Suppl. S8):819. doi: 10.1186/s12864-017-4188-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12864-017-4188-2</ArticleId>
            <ArticleId IdType="pmc">PMC5688471</ArticleId>
            <ArticleId IdType="pubmed">29143597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinlivan R., Buckley J., James M., Twist A., Ball S., Duno M. McArdle disease: A clinical review. J. Neurol. Neurosurg. Psychiatry. 2010;81:1182–1188. doi: 10.1136/jnnp.2009.195040.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2009.195040</ArticleId>
            <ArticleId IdType="pubmed">20861058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Braakhekke J.P., De Bruin M.I., Stegeman D.F., Wevers R.A., Binkhorst R.A., Joosten E.M.G. The second wind phenomenon in McArdle’s disease. Brain. 1986;109:1087–1101. doi: 10.1093/brain/109.6.1087.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/109.6.1087</ArticleId>
            <ArticleId IdType="pubmed">3466659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haller R.G., Vissing J. Spontaneous “second wind” and glucose-induced second “second wind” in McArdle disease: Oxidative mechanisms. Arch. Neurol. 2002;59:1395–1402. doi: 10.1001/archneur.59.9.1395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.59.9.1395</ArticleId>
            <ArticleId IdType="pubmed">12223025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Luna N., Brull A., Lucia A., Santalla A., Garatachea N., Martí R. PYGM expression analysis in white blood cells: A complementary tool for diagnosing McArdle disease? Neuromuscul. Disord. 2014;24:1079–1086. doi: 10.1016/j.nmd.2014.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2014.08.002</ArticleId>
            <ArticleId IdType="pubmed">25240406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santalla A., Munguía-Izquierdo D., Brea-Alejo L., Pagola-Aldazábal I., Díez-Bermejo J., Fleck S.J., Lucia A. Feasibility of resistance training in adult McArdle patients: Clinical outcomes and muscle strength and mass benefits. Front. Aging Neurosci. 2014;6:334. doi: 10.3389/fnagi.2014.00334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnagi.2014.00334</ArticleId>
            <ArticleId IdType="pmc">PMC4263173</ArticleId>
            <ArticleId IdType="pubmed">25566067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santalla A., Nogales-Gadea G., Ørtenblad N., Brull A., de Luna N., Pinós T., Lucia A. McArdle disease: A unique study model in sports medicine. Sports Med. 2014;44:1531–1544. doi: 10.1007/s40279-014-0223-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40279-014-0223-5</ArticleId>
            <ArticleId IdType="pubmed">25028051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukui T., Shimomura S., Nakano K. Potato and rabbit muscle phosphorylases: Comparative studies on the structure, function and regulation of regulatory and nonregulatory enzymes. Mol. Cell. Biochem. 1982;42:129–144. doi: 10.1007/BF00238507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF00238507</ArticleId>
            <ArticleId IdType="pubmed">7062910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson L.N. Glycogen phosphorylase: Control by phosphorylation and allosteric effectors. FASEB J. 1992;6:2274–2282. doi: 10.1096/fasebj.6.6.1544539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1096/fasebj.6.6.1544539</ArticleId>
            <ArticleId IdType="pubmed">1544539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Richter F., Bohme H.J., Hofmann E. Developmental changes of glycogen phosphorylase b isozymes in rat tissues. Biomed. Biochim. Acta. 1983;42:1229–1235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6426476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato K., Satoh K., Sato T., Imai F., Morris H.P. Isozyme patterns of glycogen phosphorylase in rat tissues and transplantable hepatomas. Cancer Res. 1976;36:487–495.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">177201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barford D., Johnson L.N. The allosteric transition of glycogen phosphorylase. Nature. 1989;340:609–616. doi: 10.1038/340609a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/340609a0</ArticleId>
            <ArticleId IdType="pubmed">2770867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barford D., Johnson L.N. The molecular mechanism for the tetrameric association of glycogen phosphorylase promoted by protein phosphorylation. Protein Sci. 1992;1:472–493. doi: 10.1002/pro.5560010403.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pro.5560010403</ArticleId>
            <ArticleId IdType="pmc">PMC2142214</ArticleId>
            <ArticleId IdType="pubmed">1304350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llavero F., Arrazola Sastre A., Luque Montoro M., Martín M.A., Arenas J., Lucia A., Zugaza J.L. Small GTPases of the Ras superfamily and glycogen phosphorylase regulation in T cells. Small GTPases. 2019 doi: 10.1080/21541248.2019.1665968.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/21541248.2019.1665968</ArticleId>
            <ArticleId IdType="pmc">PMC7849735</ArticleId>
            <ArticleId IdType="pubmed">31512989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled receptors. J. Cell Physiol. 2007;213:589–602. doi: 10.1002/jcp.21246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jcp.21246</ArticleId>
            <ArticleId IdType="pubmed">17786953</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andreeva I.E., Rice N.A., Carlson G.M. The regulatory alpha subunit of phosphorylase kinase may directly participate in the binding of glycogen phosphorylase. Biochemistry. 2002;67:1197–1202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12460118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buchbinder J.L., Luong C.B., Browner M.F., Fletterick R.J. Partial activation of muscle phosphorylase by replacement of serine 14 with acidic residues at the site of regulatory phosphorylation. Biochemistry. 1997;36:8039–8044. doi: 10.1021/bi9704820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi9704820</ArticleId>
            <ArticleId IdType="pubmed">9201951</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer E.H. Cellular regulation by protein phosphorylation. Biochem. Biophys. Res. Commun. 2013;430:865–867. doi: 10.1016/j.bbrc.2012.10.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2012.10.024</ArticleId>
            <ArticleId IdType="pubmed">23058924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waraich R.S., Weigert C., Kalbacher H., Hennige A.M., Lutz S.Z., Häring H.U. Phosphorylation of Ser357 of rat insulin receptor substrate-1 mediates adverse effects of protein kinase C-delta on insulin action in skeletal muscle cells. J. Biol. Chem. 2008;283:11226–11233. doi: 10.1074/jbc.M708588200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M708588200</ArticleId>
            <ArticleId IdType="pubmed">18285345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Defer N., Best-Belpomme M., Hanoune J. Tissue specificity and physiological relevance of various isoforms of adenylyl cyclase. Am. J. Physiol. Renal Physiol. 2000;279:F400–F416. doi: 10.1152/ajprenal.2000.279.3.F400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajprenal.2000.279.3.F400</ArticleId>
            <ArticleId IdType="pubmed">10966920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beazely M.A., Alan J.K., Watts V.J. Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. Mol. Pharm. 2005;67:250–259. doi: 10.1124/mol.104.001370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.104.001370</ArticleId>
            <ArticleId IdType="pubmed">15470083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beazely M.A., Watts V.J. Regulatory properties of adenylate cyclases type 5 and 6: A progress report. Eur. J. Pharm. 2006;535:1–12. doi: 10.1016/j.ejphar.2006.01.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejphar.2006.01.054</ArticleId>
            <ArticleId IdType="pubmed">16527269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llavero F., Montoro M.L., Sastre A.A., Fernández-Moreno D., Lacerda H.M. Epidermal growth factor receptor controls glycogen phosphorylase in T cells through small GTPases of the RAS family. J. Biol. Chem. 2019;294:4345–4358. doi: 10.1074/jbc.RA118.005997.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.RA118.005997</ArticleId>
            <ArticleId IdType="pmc">PMC6433075</ArticleId>
            <ArticleId IdType="pubmed">30647127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Browner M.F., Fauman E.B., Fletterick R.J. Tracking conformational states in allosteric transitions of phosphorylase. Biochemistry. 1992;31:11297–11304. doi: 10.1021/bi00161a006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/bi00161a006</ArticleId>
            <ArticleId IdType="pubmed">1445867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lukacs C.M., Oikonomakos N.G., Crowther R.L., Hong L.N., Kammlott R.U., Levin W. The crystal structure of human muscle glycogen phosphorylase a with bound glucose and AMP: An intermediate conformation with T-state and R-state features. Proteins. 2006;63:1123–1126. doi: 10.1002/prot.20939.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/prot.20939</ArticleId>
            <ArticleId IdType="pubmed">16523484</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newgard C.B., Hwang P.K., Fletterick R.J. The family of glycogen phosphorylases: Structure and function. Crit. Rev. Biochem. Mol. Biol. 1989;24:69–99. doi: 10.3109/10409238909082552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3109/10409238909082552</ArticleId>
            <ArticleId IdType="pubmed">2667896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fletterick R.J., Burke J.A., Hwang P.K., Nakano K., Newgard C.B. Structural relationships in glycogen phosphorylases. Ann. N. Y. Acad. Sci. 1986;478:220–232. doi: 10.1111/j.1749-6632.1986.tb15533.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1986.tb15533.x</ArticleId>
            <ArticleId IdType="pubmed">3541750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madsen N.B., Avramovic-Zikic O., Honikel K.O. Structure-function relationships in glycogen phosphorylase with respect to its control characteristics. Ann. N. Y. Acad. Sci. 1973;210:222–237. doi: 10.1111/j.1749-6632.1973.tb47575.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1749-6632.1973.tb47575.x</ArticleId>
            <ArticleId IdType="pubmed">4512312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arrizabalaga O., Lacerda H.M., Zubiaga A.M., Zugaza J.L. Rac1 protein regulates glycogen phosphorylase activation and controls interleukin (IL)-2-dependent T cell proliferation. J. Biol. Chem. 2012;287:11878–11890. doi: 10.1074/jbc.M111.297804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M111.297804</ArticleId>
            <ArticleId IdType="pmc">PMC3320936</ArticleId>
            <ArticleId IdType="pubmed">22337875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llavero F., Artaso A., Lacerda H.M., Parada L.A., Zugaza J.L. Lck/PLCgamma control migration and proliferation of interleukin (IL)-2-stimulated T cells via the Rac1 GTPase/glycogen phosphorylase pathway. Cell. Signal. 2016;28:1713–1724. doi: 10.1016/j.cellsig.2016.07.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2016.07.014</ArticleId>
            <ArticleId IdType="pubmed">27519475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Llavero F., Urzelai B., Osinalde N., Gálvez P., Lacerda H.M., Parada L.A., Zugaza J.L. Guanine nucleotide exchange factor alphaPIX leads to activation of the Rac 1 GTPase/glycogen phosphorylase pathway in interleukin (IL)-2-stimulated T cells. J. Biol. Chem. 2015;290:9171–9182. doi: 10.1074/jbc.M114.608414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M114.608414</ArticleId>
            <ArticleId IdType="pmc">PMC4423703</ArticleId>
            <ArticleId IdType="pubmed">25694429</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chasiotis D. The regulation of glycogen phosphorylase and glycogen breakdown in human skeletal muscle. Acta Physiol. Scand Suppl. 1983;518:1–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6139934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hue L., Bontemps F., Hers H. The effects of glucose and of potassium ions on the interconversion of the two forms of glycogen phosphorylase and of glycogen synthetase in isolated rat liver preparations. Biochem. J. 1975;152:105–114. doi: 10.1042/bj1520105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/bj1520105</ArticleId>
            <ArticleId IdType="pmc">PMC1172445</ArticleId>
            <ArticleId IdType="pubmed">813634</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Consuegra I., Rubio J.C., Nogales-Gadea G., Bautista J., Jimenez S., Cabello A., Lucía A., Andreu A.L., Arenas J., Martin M.A. Novel mutations in patients with McArdle disease by analysis of skeletal muscle mRNA. J. Med. Genet. 2009;46:198–202. doi: 10.1136/jmg.2008.059469.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jmg.2008.059469</ArticleId>
            <ArticleId IdType="pubmed">19251976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Brull A., Santalla A., Andreu A.L., Arenas J., Martín M., Lucia A., de Luna N., Pinós T.A. McArdle Disease: Update of Reported Mutations and Polymorphisms in the PYGM Gene. Hum. Mutat. 2015;36:669–678. doi: 10.1002/humu.22806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.22806</ArticleId>
            <ArticleId IdType="pubmed">25914343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujino S., Shanske S., DiMauro S. Molecular genetic heterogeneity of myophosphorylase deficiency (McArdle’s disease) N. Engl. J. Med. 1993;329:241–245. doi: 10.1056/NEJM199307223290404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJM199307223290404</ArticleId>
            <ArticleId IdType="pubmed">8316268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DiMauro S., Hartlage P.L. Fatal infantile form of muscle phosphorylase deficiency. Neurology. 1978;28:1124–1129. doi: 10.1212/WNL.28.11.1124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.28.11.1124</ArticleId>
            <ArticleId IdType="pubmed">101896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martín M.A., Rubio J.C., Buchbinder J., Fernández-Hojas R., Del Hoyo P., Teijeira S., Gámez J., Navarro C., Fernández J.M., Cabello A., et al.  Molecular heterogeneity of myophosphorylase deficiency (McArdle’s disease): A genotype-phenotype correlation study. Ann. Neurol. 2001;50:574–581. doi: 10.1002/ana.1225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.1225</ArticleId>
            <ArticleId IdType="pubmed">11706962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y., Weber J.L., Vladutiu G.D., Tarnopolsky M.A. Six novel mutations in the myophosphorylase gene in patients with McArdle disease and a family with pseudo-dominant inheritance pattern. Mol. Genet. Metab. 2011;104:587–591. doi: 10.1016/j.ymgme.2011.08.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ymgme.2011.08.012</ArticleId>
            <ArticleId IdType="pubmed">21880526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell J.M., Walker K.R., Creed K.E., Dunton E., Davies L., Quinlivan R., Karpati G. Phosphorylase re-expression, increase in the force of contraction and decreased fatigue following notexin-induced muscle damage and regeneration in the ovine model of McArdle disease. Neuromuscul. Disord. 2014;24:167–177. doi: 10.1016/j.nmd.2013.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2013.10.003</ArticleId>
            <ArticleId IdType="pubmed">24309536</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinuzzi A., Vergani L., Carrozzo R., Fanin M., Bartoloni L., Angelini C., Askanas V., Engel W.K. Expression of muscle-type phosphorylase in innervated and aneural cultured muscle of patients with myophosphorylase deficiency. J. Clin. Investig. 1993;92:1774–1780. doi: 10.1172/JCI116766.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI116766</ArticleId>
            <ArticleId IdType="pmc">PMC288339</ArticleId>
            <ArticleId IdType="pubmed">8408630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfeiffer-Guglielmi B., Bröer S., Bröer A., Hamprecht B. Isozyme pattern of glycogen phosphorylase in the rat nervous system and rat astroglia-rich primary cultures: Electrophoretic and polymerase chain reaction studies. Neurochem. Res. 2000;25:1485–1491. doi: 10.1023/A:1007676109206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1023/A:1007676109206</ArticleId>
            <ArticleId IdType="pubmed">11071367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinacho R., Vila E., Prades R., Tarragó T., Castro E., Ferrer I., Ramos B. The glial phosphorylase of glycogen isoform is reduced in the dorsolateral prefrontal cortex in chronic schizophrenia. Schizophr. Res. 2016;177:37–43. doi: 10.1016/j.schres.2016.04.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.schres.2016.04.024</ArticleId>
            <ArticleId IdType="pubmed">27156240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmid H., Dolderer B., Thiess U., Verleysdonk S., Hamprecht B. Renal expression of the brain and muscle isoforms of glycogen phosphorylase in different cell types. Neurochem. Res. 2008;33:2575–2582. doi: 10.1007/s11064-008-9640-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-008-9640-x</ArticleId>
            <ArticleId IdType="pubmed">18338248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jakobsen E., Bak L.K., Walls A.B., Reuschlein A.K., Schousboe A., Waagepetersen H.S. Glycogen Shunt Activity and Glycolytic Supercompensation in Astrocytes May Be Distinctly Mediated via the Muscle Form of Glycogen Phosphorylase. Neurochem. Res. 2017;42:2490–2494. doi: 10.1007/s11064-017-2267-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11064-017-2267-z</ArticleId>
            <ArticleId IdType="pubmed">28497340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfeiffer-Guglielmi B., Fleckenstein B., Jung G., Hamprecht B. Immunocytochemical localization of glycogen phosphorylase isozymes in rat nervous tissues by using isozyme-specific antibodies. J. Neurochem. 2003;85:73–81. doi: 10.1046/j.1471-4159.2003.01644.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1046/j.1471-4159.2003.01644.x</ArticleId>
            <ArticleId IdType="pubmed">12641728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alsberge J.B., Chen J.J., Zaidi A.A., Fu A.D. Retinal Dystrophy in a Patient with Mcardle Disease. Retin. Cases Brief Rep. 2018 doi: 10.1097/ICB.0000000000000790.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/ICB.0000000000000790</ArticleId>
            <ArticleId IdType="pubmed">30074569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leonardy N.J., Harbin R.L., Sternberg P., Jr. Pattern dystrophy of the retinal pigment epithelium in a patient with McArdle’s disease. Am. J. Ophthalmol. 1988;106:741–742. doi: 10.1016/0002-9394(88)90713-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0002-9394(88)90713-1</ArticleId>
            <ArticleId IdType="pubmed">3195655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez-Gómez I., Santalla A., Diez-Bermejo J., Munguía-Izquierdo D., Alegre L.M., Nogales-Gadea G. A New Condition in McArdle Disease: Poor Bone Health-Benefits of an Active Lifestyle. Med. Sci. Sports Exerc. 2018;50:3–10. doi: 10.1249/MSS.0000000000001414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1249/MSS.0000000000001414</ArticleId>
            <ArticleId IdType="pubmed">29251685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carlson G.M., Dienel G.A., Colbran R.J. Introduction to the Thematic Minireview Series: Brain glycogen metabolism. J. Biol. Chem. 2018;293:7087–7088. doi: 10.1074/jbc.TM118.002642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.TM118.002642</ArticleId>
            <ArticleId IdType="pmc">PMC5950002</ArticleId>
            <ArticleId IdType="pubmed">29514979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kanungo S., Wells K., Tribett T., El-Gharbawy A. Glycogen metabolism and glycogen storage disorders. Ann. Transl. Med. 2018;6:474. doi: 10.21037/atm.2018.10.59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.21037/atm.2018.10.59</ArticleId>
            <ArticleId IdType="pmc">PMC6331362</ArticleId>
            <ArticleId IdType="pubmed">30740405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Prats C., Graham T.E., Shearer J. The dynamic life of the glycogen granule. J. Biol. Chem. 2018;293:7089–7098. doi: 10.1074/jbc.R117.802843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.R117.802843</ArticleId>
            <ArticleId IdType="pmc">PMC5949993</ArticleId>
            <ArticleId IdType="pubmed">29483195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alberini C.M., Cruz E., Descalzi G., Bessières B., Gao V. Astrocyte glycogen and lactate: New insights into learning and memory mechanisms. Glia. 2018;66:1244–1262. doi: 10.1002/glia.23250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.23250</ArticleId>
            <ArticleId IdType="pmc">PMC5903986</ArticleId>
            <ArticleId IdType="pubmed">29076603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wender R., Brown A.M., Fern R., Swanson R.A., Farrell K., Ransom B.R. Astrocytic glycogen influences axon function and survival during glucose deprivation in central white matter. J. Neurosci. 2000;20:6804–6810. doi: 10.1523/JNEUROSCI.20-18-06804.2000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.20-18-06804.2000</ArticleId>
            <ArticleId IdType="pmc">PMC6772835</ArticleId>
            <ArticleId IdType="pubmed">10995824</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magistretti P.J., Morrison J.H., Shoemaker W.J., Sapin V., Bloom F.E. Vasoactive intestinal polypeptide induces glycogenolysis in mouse cortical slices: A possible regulatory mechanism for the local control of energy metabolism. Proc. Natl. Acad. Sci. USA. 1981;78:6535–6539. doi: 10.1073/pnas.78.10.6535.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.78.10.6535</ArticleId>
            <ArticleId IdType="pmc">PMC349075</ArticleId>
            <ArticleId IdType="pubmed">6118864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorg O., Magistretti P.J. Characterization of the glycogenolysis elicited by vasoactive intestinal peptide, noradrenaline and adenosine in primary cultures of mouse cerebral cortical astrocytes. Brain Res. 1991;563:227–233. doi: 10.1016/0006-8993(91)91538-C.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0006-8993(91)91538-C</ArticleId>
            <ArticleId IdType="pubmed">1664773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sorg O., Magistretti P.J. Vasoactive intestinal peptide and noradrenaline exert long-term control on glycogen levels in astrocytes: Blockade by protein synthesis inhibition. J. Neurosci. 1992;12:4923–4931. doi: 10.1523/JNEUROSCI.12-12-04923.1992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.12-12-04923.1992</ArticleId>
            <ArticleId IdType="pmc">PMC6575784</ArticleId>
            <ArticleId IdType="pubmed">1334506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouzier-Sore A.K., Pellerin L. Unraveling the complex metabolic nature of astrocytes. Front. Cell Neurosci. 2013;7:179. doi: 10.3389/fncel.2013.00179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2013.00179</ArticleId>
            <ArticleId IdType="pmc">PMC3795301</ArticleId>
            <ArticleId IdType="pubmed">24130515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez-Escuredo J., Van Hee V.F., Sboarina M., Falces J., Payen V.L., Pellerin L., Sonveaux P. Monocarboxylate transporters in the brain and in cancer. Biochim. Biophys. Acta. 2016;1863:2481–2497. doi: 10.1016/j.bbamcr.2016.03.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2016.03.013</ArticleId>
            <ArticleId IdType="pmc">PMC4990061</ArticleId>
            <ArticleId IdType="pubmed">26993058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carneiro L., Pellerin L. Monocarboxylate transporters: New players in body weight regulation. Obes. Rev. 2015;16(Suppl. S1):55–66. doi: 10.1111/obr.12256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/obr.12256</ArticleId>
            <ArticleId IdType="pubmed">25614204</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Love D.C., Hanover J.A. The hexosamine signaling pathway: Deciphering the “O-GlcNAc code”. Sci. STKE. 2005;312:re13. doi: 10.1126/stke.3122005re13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/stke.3122005re13</ArticleId>
            <ArticleId IdType="pubmed">16317114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang J.G., Park S.Y., Ji S., Jang I., Park S., Kim H.S. O-GlcNAc protein modification in cancer cells increases in response to glucose deprivation through glycogen degradation. J. Biol. Chem. 2009;284:34777–34784. doi: 10.1074/jbc.M109.026351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M109.026351</ArticleId>
            <ArticleId IdType="pmc">PMC2787340</ArticleId>
            <ArticleId IdType="pubmed">19833729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hurtado-Guerrero R., Dorfmueller H.C., van Aalten D.M. Molecular mechanisms of O-GlcNAcylation. Curr. Opin. Struct. Biol. 2008;18:551–557. doi: 10.1016/j.sbi.2008.09.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sbi.2008.09.005</ArticleId>
            <ArticleId IdType="pubmed">18822376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hart G.W., Slawson C., Ramirez-Correa G., Lagerlof O. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 2011;80:825–858. doi: 10.1146/annurev-biochem-060608-102511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-biochem-060608-102511</ArticleId>
            <ArticleId IdType="pmc">PMC3294376</ArticleId>
            <ArticleId IdType="pubmed">21391816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zachara N.E., Hart G.W. The emerging significance of O-GlcNAc in cellular regulation. Chem. Rev. 2002;102:431–438. doi: 10.1021/cr000406u.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cr000406u</ArticleId>
            <ArticleId IdType="pubmed">11841249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zachara N.E., Hart G.W. Cell signaling, the essential role of O-GlcNAc! Biochim. Biophys. Acta. 2006;1761:599–617. doi: 10.1016/j.bbalip.2006.04.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbalip.2006.04.007</ArticleId>
            <ArticleId IdType="pubmed">16781888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chatham J.C., Marchase R.B. Protein O-GlcNAcylation: A critical regulator of the cellular response to stress. Curr. Signal. Transduct. Ther. 2010;5:49–59. doi: 10.2174/157436210790226492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/157436210790226492</ArticleId>
            <ArticleId IdType="pmc">PMC3270492</ArticleId>
            <ArticleId IdType="pubmed">22308107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z., Udeshi N.D., Slawson C., Compton P.D., Sakabe K., Cheung W.D. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates cytokinesis. Sci. Signal. 2010;3:ra2. doi: 10.1126/scisignal.2000526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.2000526</ArticleId>
            <ArticleId IdType="pmc">PMC2866299</ArticleId>
            <ArticleId IdType="pubmed">20068230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Y.T., Luo H., Guan W.J., Zhang H., Chen C., Wang Z., Li J.D. O-GlcNAcylation of BMAL1 regulates circadian rhythms in NIH3T3 fibroblasts. Biochem. Biophys. Res. Commun. 2013;431:382–387. doi: 10.1016/j.bbrc.2013.01.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbrc.2013.01.043</ArticleId>
            <ArticleId IdType="pubmed">23337503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma Z., Vocadlo D.J., Vosseller K. Hyper-O-GlcNAcylation is anti-apoptotic and maintains constitutive NF-kappaB activity in pancreatic cancer cells. J. Biol. Chem. 2013;288:15121–15130. doi: 10.1074/jbc.M113.470047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M113.470047</ArticleId>
            <ArticleId IdType="pmc">PMC3663532</ArticleId>
            <ArticleId IdType="pubmed">23592772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeidan Q., Hart G.W. The intersections between O-GlcNAcylation and phosphorylation: Implications for multiple signaling pathways. J. Cell Sci. 2010;123:13–22. doi: 10.1242/jcs.053678.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.053678</ArticleId>
            <ArticleId IdType="pmc">PMC2794709</ArticleId>
            <ArticleId IdType="pubmed">20016062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi W., Clark P.M., Mason D.E., Keenan M.C., Hill C., Goddard W.A. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science. 2012;337:975–980. doi: 10.1126/science.1222278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1222278</ArticleId>
            <ArticleId IdType="pmc">PMC3534962</ArticleId>
            <ArticleId IdType="pubmed">22923583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi W., Gu Y., Han C., Liu H., Fan Q., Zhang X., Cong Q., Yu W. O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy. Biochim. Biophys. Acta. 2011;1812:514–519. doi: 10.1016/j.bbadis.2011.01.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbadis.2011.01.009</ArticleId>
            <ArticleId IdType="pubmed">21255644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slawson C., Hart G.W. O-GlcNAc signalling: Implications for cancer cell biology. Nat. Rev. Cancer. 2011;11:678–684. doi: 10.1038/nrc3114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3114</ArticleId>
            <ArticleId IdType="pmc">PMC3291174</ArticleId>
            <ArticleId IdType="pubmed">21850036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butkinaree C., Park K., Hart G.W. O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim. Biophys. Acta. 2010;1800:96–106. doi: 10.1016/j.bbagen.2009.07.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbagen.2009.07.018</ArticleId>
            <ArticleId IdType="pmc">PMC2815129</ArticleId>
            <ArticleId IdType="pubmed">19647786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angelos S., Valberg S.J., Smith B.P., McQuarrie P.S., Shanske S., Tsujino S., Mauro S., Cardinet G.H., III Myophosphorylase deficiency associated with rhabdomyolysis and exercise intolerance in 6 related Charolais cattle. Muscle Nerve. 1995;18:736–740. doi: 10.1002/mus.880180710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.880180710</ArticleId>
            <ArticleId IdType="pubmed">7783763</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsujino S., Shanske S., Valberg S.J., Cardinet G.H., III, Smith B.P., DiMauro S. Cloning of bovine muscle glycogen phosphorylase cDNA and identification of a mutation in cattle with myophosphorylase deficiency, an animal model for McArdle’s disease. Neuromuscul. Disord. 1996;6:19–26. doi: 10.1016/0960-8966(95)00014-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0960-8966(95)00014-3</ArticleId>
            <ArticleId IdType="pubmed">8845714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walker K.R.  Ph.D. Thesis. Murdoch University, Perth Campus; Murdoch, Western Australia: 2006. Characterization of the Ovine Model of McArdle Disease: Development of Therapeutic Strategies.</Citation>
        </Reference>
        <Reference>
          <Citation>Tan P., Allen J.G., Wilton S.D., Akkari P.A., Huxtable C.R., Laing N.G. A splice-site mutation causing ovine McArdle’s disease. Neuromuscul. Disord. 1997;7:336–342. doi: 10.1016/S0960-8966(97)00062-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0960-8966(97)00062-X</ArticleId>
            <ArticleId IdType="pubmed">9267848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howell J.M., Dunton E., Creed K.E., Quinlivan R., Sewry C. Investigating sodium valproate as a treatment for McArdle disease in sheep. Neuromuscul. Disord. 2015;25:111–119. doi: 10.1016/j.nmd.2014.10.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2014.10.002</ArticleId>
            <ArticleId IdType="pubmed">25455802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nogales-Gadea G., Pinos T., Lucia A., Arenas J., Camara Y., Brull A., de Luna N., Martín M.A., Garcia-Arumí E., Martí R., et al.  Knock-in mice for the R50X mutation in the PYGM gene present with McArdle disease. Brain. 2012;135:2048–2057. doi: 10.1093/brain/aws141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws141</ArticleId>
            <ArticleId IdType="pubmed">22730558</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brull A., de Luna N., Blanco-Grau A., Lucia A., Martin M.A., Arenas J., Martí R., Andreu A.L., Pinós T. Phenotype consequences of myophosphorylase dysfunction: Insights from the McArdle mouse model. J. Physiol. 2015;593:2693–2706. doi: 10.1113/JP270085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1113/JP270085</ArticleId>
            <ArticleId IdType="pmc">PMC4500353</ArticleId>
            <ArticleId IdType="pubmed">25873271</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fiuza-Luces C., Nogales-Gadea G., García-Consuegra I., Pareja-Galeano H., Rufián-Vázquez L., Pérez L.M., Andreu A.L., Arenas J., Martín M.A., Pinós T., et al.  Muscle Signaling in Exercise Intolerance: Insights from the McArdle Mouse Model. Med. Sci. Sports Exerc. 2016;48:1448–1458. doi: 10.1249/MSS.0000000000000931.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1249/MSS.0000000000000931</ArticleId>
            <ArticleId IdType="pubmed">27031745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Birch K.E., Quinlivan R.M., Morris G.E. Cell models for McArdle disease and aminoglycoside-induced read-through of a premature termination codon. Neuromuscul. Disord. 2013;23:43–51. doi: 10.1016/j.nmd.2012.06.348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2012.06.348</ArticleId>
            <ArticleId IdType="pubmed">22818872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steele I.C., Patterson V.H., Nicholls D.P. A double blind, placebo controlled, crossover trial of D-ribose in McArdle’s disease. J. Neurol. Sci. 1996;136:174–177. doi: 10.1016/0022-510X(95)00320-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510X(95)00320-2</ArticleId>
            <ArticleId IdType="pubmed">8815168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Luna N., Brull A., Guiu J.M., Lucia A., Martin M.A., Arenas J. Sodium valproate increases the brain isoform of glycogen phosphorylase: Looking for a compensation mechanism in McArdle disease using a mouse primary skeletal-muscle culture in vitro. Dis. Model. Mech. 2015;8:467–472. doi: 10.1242/dmm.020230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/dmm.020230</ArticleId>
            <ArticleId IdType="pmc">PMC4415898</ArticleId>
            <ArticleId IdType="pubmed">25762569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vorgerd M., Grehl T., Jäger M., Müller K., Freitag G., Patzold T. Creatine therapy in myophosphorylase deficiency (McArdle disease): A placebo-controlled crossover trial. Arch. Neurol. 2000;57:956–963. doi: 10.1001/archneur.57.7.956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.57.7.956</ArticleId>
            <ArticleId IdType="pubmed">10891977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vorgerd M., Zange J., Kley R., Grehl T., Hüsing A., Jäger M. Effect of high-dose creatine therapy on symptoms of exercise intolerance in McArdle disease: Double-blind, placebo-controlled crossover study. Arch. Neurol. 2002;59:97–101. doi: 10.1001/archneur.59.1.97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.59.1.97</ArticleId>
            <ArticleId IdType="pubmed">11790236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vorgerd M., Zange J. Treatment of glycogenosys type V (McArdle disease) with creatine and ketogenic diet with clinical scores and with 31P-MRS on working leg muscle. Acta Myol. 2007;26:61–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2949316</ArticleId>
            <ArticleId IdType="pubmed">17915573</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinlivan R., Martinuzzi A., Schoser B. Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V) Cochrane Database Syst. Rev. 2014;11:CD003458. doi: 10.1002/14651858.CD003458.pub5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD003458.pub5</ArticleId>
            <ArticleId IdType="pmc">PMC7173724</ArticleId>
            <ArticleId IdType="pubmed">25391139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinlivan R.M., Beynon R.J. Pharmacological and nutritional treatment trials in McArdle disease. Acta Myol. 2007;26:58–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2949313</ArticleId>
            <ArticleId IdType="pubmed">17915572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vissing J., Haller R.G. The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N. Engl. J. Med. 2003;349:2503–2509. doi: 10.1056/NEJMoa031836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa031836</ArticleId>
            <ArticleId IdType="pubmed">14695410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quinlivan R., Lucia A., Scalco R.S., Santana A., Parini J., Godfrey R., Marti R. Report on the EUROMAC McArdle Exercise Testing Workshop, Madrid, Spain, 11–12 July 2014. Neuromuscul. Disord. 2015;25:739–745. doi: 10.1016/j.nmd.2015.05.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2015.05.009</ArticleId>
            <ArticleId IdType="pubmed">26159598</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
